Lyell Immunopharma Amends Phase 1 Trial for Colorectal Cancer Therapy LYL273 — Lyell Immunopharma, Inc.

Event summary

Gastrointestinal prophylaxis reduced Grade ≥ 2 diarrhea/colitis from 55% to 10% in LYL273 trial patients.
Maximum tolerated dose for LYL273 has not yet been determined.
Phase 1 trial amended to Phase 1/2 design, adding second-line and radiotherapy combination cohorts.
End-of-Phase 1 FDA meeting expected in the second half of 2026.

The big picture

Lyell Immunopharma's amendment of the Phase 1 trial for LYL273 reflects a strategic shift to accelerate development timelines for its guanylyl cyclase C (GCC)-targeted CAR T-cell therapy. The focus on managing safety profiles and expanding trial cohorts aligns with broader industry trends toward optimizing CAR T-cell therapies for solid tumors, a historically challenging area. The potential for a pivotal Phase 2 trial underscores the high stakes in advancing treatments for relapsed or refractory metastatic colorectal cancer.

What we're watching

Regulatory Alignment: Whether the FDA will approve the seamless transition to a pivotal Phase 2 trial.
Safety Management: The effectiveness of gastrointestinal prophylaxis in maintaining low adverse event rates at higher doses.
Clinical Outcomes: The pace at which additional Phase 1 data, including clinical outcomes, will be reported.